Date Time
$23.3M grant awarded to international chemical safety project involving IU researchers
A project involving Indiana University researchers was awarded $23.3 million from the European Commission to shape chemical safety regulation without the use of animal testing.
IU is part of a consortium of European and U.S. organizations called PrecisionTox, led by the University of Birmingham in the U.K., that received the award. PrecisionTox, short for precision toxicology, aims to protect human health from the toxic effects of chemicals found in people’s homes, food and the environment.
Joseph Shaw. Photo courtesy of the O’Neill School of Public and Environmental Affairs.
Image: Penn State
February 18, 2021
ALTOONA, Pa. The Penn State Altoona Athletics Advisory Council announced its first Hall of Fame class on Feb. 17, naming five individuals and one team as its inaugural group of inductees.
Selected to the Penn State Altoona Athletics Hall of Fame are:
Fredina M. Ingold, Penn State Altoona Athletics administrator, 1977-2014
Jillian Klinar, women’s basketball, 2000-02
Tyler Franklin, men’s basketball, 2003-07
Tim Wassell, men’s soccer, 2004-05; women’s soccer coach, 2007-09
The 1995-96 Penn State Altoona women’s volleyball team
Dr. Richard Miller, men’s basketball, 1966-68
Ingold and Miller enter the Hall of Fame as Distinguished Achievement Inductees.
Share this article
Share this article
ROCHESTER, N.Y., Feb. 19, 2021 /PRNewswire/ Vuzix® Corporation (NASDAQ: VUZI), ( Vuzix or, the Company ), a leading supplier of Smart Glasses and Augmented Reality (AR) technology and products, today announced that the Company s Vuzix M400 Smart Glasses were featured in the American Medical Association s Special COVID-19 Edition for Accelerating Change in Medical Health Education Systems Science Student, Resident and Fellow Impact Challenge. The clinical study was conducted by the University of Louisville School of Medicine and summarized in the recent publication by the American Medical Association.
Shadowing and preceptorship opportunities allow students to get an early idea of what specialty they would like to pursue. The pandemic made it impossible for students around the country to safely get the desired exposure to patients and practicing physicians; making personal decisions regarding their specialty they would plan to pursu
(2)
EDISON, NJ / ACCESSWIRE / February 10, 2021 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA)( Hepion ), a clinical stage biopharmaceutical company focused on Artificial Intelligence ( AI )-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis ( NASH ) and liver disease, today announced the appointment of Todd M. Hobbs, M.D., to the newly created position of Chief Medical Officer ( CMO ), effective February 16, 2021.
In this role, Dr. Hobbs will help lead Hepion s engagement with the U.S. Food and Drug Administration ( FDA ), global and national thought leaders, key policymakers, and professional associations.
Dr. Hobbs joins Hepion from Novo Nordisk Inc., one of the world s leading healthcare companies. His 16 years of progressive experience at Novo Nordisk includes positions ranging from field medical affairs leadership at the start of his corporate career through to his most recent role as North American Chief Medical Officer and Vice President.